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A brief note on Silvanus Thompson
The name of Professor Silvanus Thompson will be very
well known to older members of the professions that
comprise the British Institute of Radiology and to those
interested in radiological history and the history of physics.
Others may, however, appreciate a brief synopsis [1] of the
manwho was the first President of the Ro¨ntgen Society (later
incorporated into the British Institute of Radiology).
Silvanus Thompson was born in 1851 and, a lifelong
Quaker, was appointed the science master at the Quaker
School at Bootham in York in 1873. His major interests
were light, optics and electromagnetism (Figure 1) and in
1876 he was appointed as a lecturer in physics at
University College, Bristol where he became Professor in
1878. Also in 1878 the City and Guilds of London
Institute for the Advancement of Technical Education was
founded with Finsbury College as a teaching institution.
Thompson was its Principal and Professor of Physics for
30 years and cared passionately about the technical
education of scientists and engineers. He was a renowned
teacher, skilled lecturer and wrote many biographies of
well known scientists such as Edison, Faraday, Lord
Kelvin and William Gilbert. His book collection of now
rare nineteenth and early twentieth century titles is
preserved at the Institute of Electrical Engineers. He
repeated Ro¨ntgen’s experiments the day after the discovery
was announced in the UK and gave the first public
demonstration in London on March 30th 1896.
Perhaps more surprisingly he is better known to the wider
scientific community for his little book Calculus made easy
(Figure 2) first published in 1910 and still available from web
outlets such as Amazon.com. He wrote in its preface:
‘‘Considering how many fools can calculate, it is
surprising that it should be thought either a difficult or
a tedious task for any other fool to learn how to master
the same tricks.
‘‘Some calculus-tricks are quite easy. Some are enor-
mously difficult. The fools who write the text-books of
advanced mathematics – and they are mostly clever fools –
seldom take the trouble to show you how easy the easy
calculations are. On the contrary, they seem to desire to
impress you with their tremendous cleverness by going
about it in the most difficult way.
‘‘Being myself a remarkably stupid fellow, I have had to
unteach myself the difficulties, and now beg to present to
my fellow fools the parts that are not hard. Master these
thoroughly and the rest will follow. What one fool can do,
another can.’’
Perhaps we can take this as a nice introduction to
intensity-modulated radiation therapy (IMRT) if we
substitute the acronym ‘‘IMRT’’ for ‘‘calculus’’.
Certainly many of the papers on the physics of IMRT
are extraordinarily complicated and one might even feel
some make them deliberately so. However, some of the
classic papers, whilst not trivial, present the main concepts
that are all that many want or need to know.
The author’s opinion is that there is really no need here
for another detailed review of the physics and clinical
application of IMRT. There are plenty written already
including books by Webb [2–5], the book from the 2003
AAPM Summer School [6], the report from the IMRT
Cooperative Working Group on IMRT in November 2001
[7] which can be read as a tutorial on the subject and the
IMRT Subcommittee of the AAPM Radiation Therapy
Committee report on guidance on IMRT implementation
[8]. A joint document from ASTRO and AAPM has
overviewed the whole process of implementing clinical
IMRT [9]. The British Institute of Radiology has just
Figure 1. Silvanus Thompson and apparatus for ‘‘mesmeris-
ing’’ (stimulating retinal light by magnetism).
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published a 7-part set of review articles on IMRT in the
British Journal of Radiology [10–16]. These detail literally
thousands of primary references in the peer review
literature.
In this paper, as in the 2004 Silvanus Thompson
Memorial Lecture on May 19th 2004 I shall attempt to
present, in simple terms, aspects of the physics and clinical
implementation of IMRT.
Why IMRT?
The X-ray was discovered on November 8th 1895 and,
within a year, treatment of cancer with ionising radiation
had begun. It was quite well developed within 5 years with
an important textbook published within 10 years [17]. For
some 50 years or so ‘‘boxes’’ of high dose were created by
crossfiring rectangular beams of radiation. Given most
tumours are not rectangular, when the ‘‘box’’ was designed
to encompass the tumour, unwanted irradiation of normal
tissues in the corners of the box arose. Rotation therapy
with rectangular open fields improved this to encompass
the target within a cylinder of high dose. Devices such as
blocking, to geometrically shape the fields, and the use of
wedges and compensators, to modify the depth-dose
characteristics, improved on this somewhat. However,
the ability to ‘‘shrinkwrap’’ the high-dose volume to the
target, as a piece of clingfilm would wrap an avocado pear,
is the goal. It is only achievable, for volumes with concave
surface, by means of intensity-modulated radiation
therapy (IMRT).
Possibly 30% of targets have concave surfaces. For
example, the prostate, abutted by rectum and bladder, is
kidney-bean shaped in transaxial cross section (Figure 3).
Many brain tumours, and tumours of the head and
neck, similarly present a challenge to planning for
invaginated surfaces. In other circumstances, when pro-
tecting the adjacent normal structures is more important
than uniformly irradiating the target, IMRT presents an
opportunity for this, so called, conformal avoidance. In
short, the inclusion of modulation as a planning option
widens the search space of opportunities to improve the
dose distribution or, as physicists would say, ‘‘increases the
number of degrees of freedom’’. In even better summary,
as Silvanus Thompson might have approved, ‘‘IMRT
leads to better/tighter dose distributions’’.
How IMRT?
Imaging and planning for IMRT
One might say that, even if the concepts had been
understood and the technology had been available, IMRT
before 1972 would have made no sense. Although X-ray
CT was in late gestation before this date [18] the year 1972
saw the birth of commercial CT and by 1976 had been
both developed and extensively commercialised. For the
first time diagnostic radiologists knew more precisely the
three-dimensional (3D) geometry of the tumour (or at least
the 3D geometry as measured by changed X-ray attenua-
tion). Radiotherapists were quick to see the potential of
planning for better treatment. So (to quote Harold Johns)
‘‘if you can’t see it you can’t hit it and if you can’t hit it
you can’t cure it’’. Changing negative to positive and
invoking ‘‘Silvanus-Thompson speak’’: seeing the tumour
we can aim at it and aiming radiation more accurately we
can possibly cure it. 3D imaging is the most
important component of modern radiation therapy and
other 3D techniques such as MRI, SPECT and PET
showing functional changes add to the ability to under-
stand better the tumour extent and to plan the correct 3D
target.
Figure 2. Silvanus Thompson’s famous book on calculus.
Figure 3. Shows a ‘‘classic’’ application for IMRT, to conform
the high dose to the non-uniform shape of the prostate simul-
taneously sparing dose to normal rectum and bladder.
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Once the 3D images are obtained (Figure 4) the human
patient is essentially disposed of, for the planning stage.
The patient ‘‘becomes an array of voxels’’. Using these,
contours of the target are drawn on selected slices. The
contours can be merged to create 3D target shapes (and
similarly for organs-at-risk [OAR]). Beam directions can
be chosen to substantially avoid OAR and the weights of
radiation from different beams can be computed such that
when added together the required shape of the high-dose
volume is obtained so far as the physics of the photon-
tissue interaction will allow. If the beams are just
geometrically shaped, but otherwise are of uniform
radiation, this is called geometrically conformal radiation
therapy (CFRT). If the sub-components of each beam, the
beamlets or bixels, have different intensities then this is
IMRT.
Traditionally for 3D CFRT treatment planning has been
done by ‘‘forward techniques’’. The dose distribution is
prescribed; the planner tries a number of different
combinations of beam direction and weight until they
are ‘‘satisfied’’ that the result is ‘‘as good as possible’’. This
is informed guesswork but somehow quaintly out of
synchrony with the input technology. ‘‘Inverse planning’’
conversely informs a computer of the prescription, the
constraints on the problem, both dosimetric and mechan-
ical, certain preset choices such as number of beams, beam
energy and maybe directions and then a computer
algorithm works out the modulations required (Figure 5).
This was unheard of 15 years ago and is now
commonplace, well understood and almost automatic.
Whilst there are still issues of debate and interest in inverse
planning the problems are largely solved. A review written
4 years ago would have concluded that inverse planning is
absolutely required for IMRT. Now many subtly modified
forward-planning methods are being developed. One in
particular directly optimizes a few geometrical shapes so
they are easy to deliver and still generate sufficient
modulation to not compromise conformality. Silvanus
Thompson’s summary would have been: use 3D images
wisely; prioritise the importance of the selection of the
target. Decide which parameters will be fixed and which
will be computer optimized. Use the algorithms available
but check their predictions against the requirements
manually. Use the simplest modulation that does the job
(which will vary from target to target).
Delivery of IMRT
There are two main classes of ways to modulate the
beam intensity for IMRT: (i) those which do so by spatial
variation directly and (ii) those which achieve the same
spatial modulation by temporal means. In class (i) are the
compensator, the multiple-static multileaf collimator
(MSF MLC) method. In class (ii) are tomotherapy, the
dynamic MLC (dMLC) technique, swept pencils, the
scanning bar. Robotic IMRT is hard to classify having
aspects of both (see later).
IMRT by spatial variation
If a piece of metal of varying thickness is put between
source and patient fewer X-rays per unit time emerge
where the metal is thickest and vice versa. Since X-ray
attenuation is exponential, the relationship between
thickness and intensity is non-linear. This method of
modulating the intensity has been in use since the mid 20th
century and the metal devices are called compensators
(Figure 6).
Figure 4. 3D data deduced from X-ray CT images. OAR,
organ at risk.
Figure 5. Just two (of several) modulated beams create an
invaginated contour for the high-dose volume.
Figure 6. Components of an ‘‘Ellis compensator’’.
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They can be built of Lego(TM)-like blocks (Ellis
compensator), of thin sheets of lead glued together, of
cast metal, of poured lead or tungsten granules, of piston-
deformed lead putty and a host of equivalents. Mostly
they were designed for missing tissue compensation, hence
their name. Early users would not have recognised the
words IMRT in connection with their use. They still have
their strong supporters given that their spatial resolution is
not limited by any collimation, they can have a large
dynamic range with continuous intensity levels and they
suffer no artefacts from collimation leaves and require no
verification of collimation. They also have a very
‘‘Silvanus Thompson simplicity’’ of understanding. ‘‘Less
comes out where the metal is thickest’’. Any fool can
understand them. A more clever fool will recognise that
there are some more complex issues such as the need to
consider beam hardening, scatter, minimum-intensity level
and so on.
The so called MSF-MLC technique (Figure 7) is
predicated on the fact that if several fields of different
geometrical shape and different intensities are superposed
(from the same direction) then a modulated intensity will
result. Given the widespread availability of the MLC and
that it is supported by all of the major electrotechnical
manufacturers for IMRT, this is now becoming a method
of choice for implementing IMRT. The pioneering
experiment showing this technique was made by Bortfeld
and Boyer in 1993, by hand-resetting each subfield and
delivering a modulation to a sliced-bread phantom (body
phantom in slices with film sandwiched in the slices).
The films were digitised and 3D plots of dose were
drawn by hand (Figure 8).
Clearly any fool can visualize how this works. Yet this is
an area of IMRT with which Silvanus Thompson would
have been particularly grumpy. The papers on techniques
to decompose modulated fields into subcomponents have
become impossibly complicated, maybe unnecessarily so.
Mathematicians, group theorists and graph theorists have
waded in and developed a bewildering armament of
methods. As far as this fool can understand, the paper by
Langer et al [19] presents the best and definitive method to
decompose modulated fields with minimum number of
both components and monitor units (so giving the fastest
treatment time and the smallest chance of leakage
contamination). But this fool may not have the complete
picture because there are still papers appearing claiming
unsolved issues.
IMRT by temporal variation
A spatial modulation of intensity will be generated if a
pair of jaws moves from a position of total closure one
side of a field to total closure at the other side, varying the
width between the jaws en route. To a first approximation
the intensity at any point in the field will be given by the
difference between the arrival time of the trailing jaw and
that of the leading jaw. If the field is instead broken up
into strips with each strip irradiated by a pair of MLC
leaves then the same statement holds for each leaf track.
The resulting field is then modulated in 2D. Any fool can
see that. A more clever fool will observe that this is further
complicated by leaf transmission (leakage), interleaf
leakage, behaviour in the regions of the tongues and
grooves of the leaf sides, head scatter from the collimation,
finite spot size of radiation focal spot, effects of gravity on
the MLC, effects of mispositioning of MLC leaves and
errors due to the difficulty of precise positioning, machine
constraints on interdigitation, effects of finite maximum
leafspeed, effects of finite acceleration and deceleration
times and so on. Many papers and reviews sort out these
difficulties which are now largely understood. The
resulting delivery technique is called the dynamic MLC
(dMLC) method. It was the one first used by Elekta
although all the accelerator manufacturers now offer
MSF-MLC instead.
A totally different method of generating a spatial
modulation through temporal modulation is tomotherapy
which may be either slice-based or spiral. In slice-based
tomotherapy the radiation is collimated to a narrow slit
longitudinally.
In the slit beam resides a multivane intensity modulating
collimator (MIMiC) with attenuating vanes which may
(a) (b)
Figure 7. Essence of the multiple-static multileaf collimator (MSF-MLC) technique. Thomas Bortfeld first described the step-and-
shoot MLC technique in 1993. (a) Approximate profile by steps. (b) Leaf sweep realisation.
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move into the slit for pre-defined times. Where the
dwelltime of the vane is highest the intensity will be
lowest and vice versa. As the vanes execute their motion
the gantry rotates almost a full circle. A 2D conformal
dose results in the irradiated slice (in practice two slices are
irradiated together as there are two sets of vanes per slice –
one from each side). To irradiate a larger volume the
patient is shunted along by a slice width and the process
repeated. Any fool can see that. A more clever fool will
consider the effects of slice abutment, the effects of
adjacent vane interference, the finite push-pull time of the
vanes, intervane and through-vane leakage, tongue-and-
groove effects, head scatter, the effect of larger numbers of
MUs, stability of rotation speed, correction for glitched
vane transitions and so on. This form of tomotherapy was
first introduced by the NOMOS Corporation in 1992 and
the first patients were treated in March 1994. The
technology had the clinical competitive lead for several
years over any other form of IMRT (except of course
compensators).
Now imagine that instead of two banks of vanes there
is just one and that the gantry rotates continuously
through many revolutions and that the patient slides
longitudinally simultaneously and one has the alterna-
tive spiral Tomotherapy, the design pioneered in 1993 by
Rock Mackie and commercially available since 2002
(Figure 9). Any fool can see the basic workings but a
more clever fool is needed to grasp the concepts of pitch,
pitch artefacts, modulation factors, transmission effects,
leakage, etc.
The main methods of IMRT delivery have now been
mentioned, and those in regular clinical use. Less used but
conceptually possible are IMRT through sweeping a pencil
beam in which the intensity is proportional to the
dwelltime of the beam, sweeping a 1D attenuating bar,
in which the intensity decreases with increasing dwelltime
Figure 9. Tomotherapy.
Figure 8. Pre-computer-3D dose dis-
play by Art(ist) Boyer. In 1993
Thomas Bortfeld and Art Boyer made
the first IMRT step-and-shoot delivery
in Houston using a Varian machine
and taking about 3 hours to reset
fields by hand. They drew this graphic
3D display of dose.
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and the use of the robotic Cyberknife to which we shall
return.
Clinical IMRT
The first clinical IMRT with modern technology for
delivery was in March 1994 at Baylor College of Medicine
using the NOMOS MIMiC technique for head and neck
cancer. During 1995 IMRT via use of the conventional
MLC began at Memorial Sloan Kettering Cancer Centre
(MSKCC) in New York for treatment of the prostate.
Clinical Tomotherapy began in August 2002. Whilst some
bladder fields were modulated at the Christie Hospital,
Manchester prior to this date, the first clinical IMRT in
the UK in which all fractions of all fields were modulated
took place at the Royal Marsden NHS Foundation Trust
on September 20th 2000.
Short of writing a textbook (of which there are some
already) on IMRT it is as futile to try to review all clinical
IMRT as it is to review all the physics developments in
detail. By the time of writing (July 2004) there are now
hundreds of centres participating in clinical IMRT. There
are also thousands of papers reporting the potential
advantages of IMRT through analysis of improved dose
distributions consequent on its use. However the number
of IMRT implementations which report actual clinical
benefit rather than potential or hoped-for benefit is still
finite and just about countable.
That there is so little hard evidence for the utility of
IMRT is for three reasons: (i) first in the USA, where the
majority of clinical IMRT has been so far performed, there
is a culture of implementing new technology ‘‘because it is
there’’ based on principles of enterprise, financial insur-
ance reimbursement and state-to-state/centre-to-centre
equality. Some argue that fully randomized phase-3
trials are unlikely to be undertaken in the USA although
there are a few notable exceptions; (ii) much of the
predicted benefit of IMRT is in the reduction of late
radiation normal-tissue complications which by definition
are too early to observe; (iii) whilst the strongest ‘‘level-1’’
evidence for clinical utility will come from randomized
trials, these are hard to set up and some are arguing that,
given the unequivocally improved dose distributions, it
may even be unethical to randomize patients when one
arm is predicted poorer outcome. Altogether this is a
complex debate.
Against this background now follows a brief list of
studies which have shown actual clinical benefit of
IMRT:
(i) Following dose escalation to the prostate at
MSKCC fewer rectal complications have been
observed than would have been observed with
conventional radiotherapy [20].
(ii) Mundt et al [21] reported absence of high-grade
early gastrointestinal and genitourinary toxicity in
IMRT of the pelvis for gynaecological malignancy.
(iii) De Meerleer et al [22] and Teh et al [23] reported
reduced rectal toxicity in groups of patients receiv-
ing IMRT of the prostate.
(iv) Following parotid-sparing IMRT for oropharyngeal
carcinoma at the Mallinckrodt Institute of
Radiology salivary flow measurements showed
improved late parotid function compared with
conventional radiotherapy [24].
(v) Maes et al [25] have shown reduced xerostomia
following bilateral elective neck irradiation. Kwong
et al [26], Patel et al [27], Lee et al [28] and Mu¨nther
et al [29] have also shown reduced xerostomia.
(vi) Claus et al [30] have shown reduced dry-eye
syndrome following IMRT for sinonasal tumours.
(vii) Yarnold et al [31] have presented a preliminary
analysis of a randomized phase-3 trial between
IMRT of the whole breast and conventional 2-
tangent irradiation. A change in breast appearance
was scored in 52% of patients in the conventional
arm but only 36% of patients in the IMRT arm.
(viii) Finally there have been several trials showing
improved clinical outcome of geometrically con-
formal CFRT but these, not being IMRT, are not
listed here.
Examples of clinical IMRT from the Royal
Marsden NHS Foundation Trust
It was shown in the mid-to-late 1990s that by modu-
lating the intensity of the two tangential fields the dose
homogeneity to the breast could be improved [32]. Subse-
quently a phase-3 randomized trial was completed with
160 women in each arm of the trial comparing
conventional unmodulated tangential-field irradiation
with modulated tangential fields. The results are being
analysed [31].
The first pelvic clinical IMRT at the Royal Marsden
NHS Foundation Trust was a phase-1 trial of IMRT of
prostate plus pelvic nodes. The goal was to deliver 70 Gy
to the prostate and initially 50 Gy to pelvic lymph nodes,
subsequently escalated to 55 Gy and 60 Gy. The small-
bowel toxicity was minimized by keeping dose less than
45 Gy. Five fields were selected (PA, L- and R-lateral and
AO at¡30˚ to anterior. The treatments were carried out at
both Sutton and Chelsea branches of the hospital. At
Sutton, planning was initially using the NOMOS
CORVUS system, then the Nucletron HELAX system
and then the ADAC PINNACLE system [33]. Treatment
planning at Chelsea used the Varian HELIOS system.
Treatment at Sutton was on Elekta accelerators and at
Chelsea on Varian accelerators [34]. Initially at Sutton the
Elekta dMLC technique was used, subsequently changed
to step-and-shoot. Quality was assured by repeating a
Bortfeld-Boyer experiment (Figure 10) on an anthropo-
morphic phantom with film and thermoluminescent
dosemeters (TLDs) and also by irradiating film strapped
to the gantry head. The work at Sutton was performed in
the context of the Elekta International IMRT Consortium.
The first patient was treated at Sutton in September 2000
and at Chelsea in July 2001.
Head and neck IMRT commenced at Chelsea in April
2002 and at Sutton in August 2003. Class solutions
were developed for the larynx, base of tongue and
thyroid tumours with involved neck nodes. The target
dose was 65 Gy and nodal dose 54 Gy with the challenge
to protect the spinal cord and oesophagus and parotid
glands.
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The future of technology for IMRT
Solutions already exist for planning and delivering
IMRT and clinical work is well underway. This is not to
say that there are no unsolved problems in planning and
delivery but there may be areas better worthy of the
limited research resources available. We are very good at
depositing highly conformal dose distributions to targets
that are unequivocally determined in tissue-equivalent
material and in absolutely static patients. However,
patients move and targets are not unequivocally deter-
mined by X-ray CT. Hence the growth area is image-
guided (IG) radiation therapy (IG-IMRT). Images, both
anatomical and functional, may be used to improve target
definition to account for differences in hypoxia and
tumour proliferation. Imaging can also be used to monitor
the motion of internal organs and to plan image-guided
treatment delivery.
As an example of the use of imaging to plan therapy
Cu(II) diacetyl-bis methylthiosemicarbazone (ATSM) has
been used to image tumour hypoxia [35] and it can be
speculated that, knowing the distribution of hypoxia,
‘‘dose painting’’ can be performed delivering deliberately
inhomogeneous dose to the tumour [36]. A second example
is that if SPECT uptake of radiopharmaceutical shows
areas of unperfused lung then these could be useful
pathways into lung tumours compared with passing
radiation through well perfused lung.
External intrafraction tissue motion can be observed by
imaging active or passive infrared markers or optical
interferometry. Internal intrafraction tissue motion can be
observed by X-ray imaging of implanted (gold grain)
markers [37], by ultrasound [38] and by magnetic
monitoring [39]. Outstanding research issues include:
(i) how to relate internal to external motion [40]
(Figure 11); (ii) how to intervene therapy via gating [41],
breath-hold [42], forced breathing [43], active breathing
control [44] or tracking [40]; (iii) whether to believe the
reproducibility of intrafraction motion.
What might Silvanus Thompson have made of
IMRT in 2004?
Albeit that the invoking of the name of Silvanus
Thomspon throughout this text is clearly an artificial
construct, it nevertheless reminds us to ‘‘strip away the
unwanted complexity’’ as he would have done when
teaching. So what would he have made of the IMRT scene
in 2004 and what would he have extracted for teaching?
Clearly whatever I write is surmise but it serves as a
conclusion as it did in my Lecture. Silvanus would have said:
(i) In 1988 when inverse planning seriously began there
was no IMRT delivery equipment except the
compensator;
(ii) In 1992 MIMiC slice tomotherapy became available;
(iii) In 1994 the MLC MSF and the dMLC method had
been operated by a few centres in a research setting;
(iv) By the mid 1990s all the main planning techniques
had been worked out and the main methods of
IMRT delivery had been shown to work at least in a
research setting;
(v) By 2000 commercial MLC/Linac manufacturers had
made available MSF-MLC and dMLC technique
linked to inverse planning;
(vi) In 2004 the MIMiC has still delivered the most
IMRT but the MLC techniques are catching up;
(vii) Many centres in Europe, USA and Asia regard
IMRT as a clinical necessity;
(viii) Clinical implementation still requires multiskills of
doctors, physicists, radiographers, engineers all
working together. It is not quite ‘‘turn key’’;
Figure 11. The motion of internal markers is detected by
X-rays; motion of external markers is detected by infrared.
Motions are correlated every 10 s. Monitor of external markers
by infrared then translates to movement of internal tumour
markers in almost real-time and this is fed back to the robot [40].
Figure 10. Quality assurance of the
pelvic IMRT via a Bortfeld-Boyer
experiment. Upper right shows the
measured dose distribution in a slice
and lower right shows the calculated
distribution.
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(ix) Patients will use the internet to seek ‘‘best
treatment’’; be prepared for that;
(x) The press will publicise IMRT (Figure 12). This is
good for showing the positive side of radiation and
for encouraging interest and investment in medical
technology. It may not be so good for patients and
relatives who expect the advertised wares to be
widely and immediately available;
(xi) Watch out for robotics (especially for motion
correction), for simpler IMRT (to meet a call
from less well off places) and (possibly and sadly)
an anti-IMRT backlash from diehards.
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